Gastric Cancer

>

Latest News

Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer
Zolbetuximab Scores FDA Approval in CLDN 18.2+ Gastric/GEJ Cancer

October 18th 2024

This approval marks the first CLDN 18.2-targeted therapy in this patient population.

T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer
T-DXd Combinations Effective in HER2+ Gastric and GEJ Cancer

September 14th 2024

FDA’S ODAC to Discuss PD-L1 Levels for ICIs in Gastric and Esophageal Cancers
FDA’S ODAC to Discuss PD-L1 Levels for ICIs in Gastric and Esophageal Cancers

August 27th 2024

Impactful Studies Challenge the Status Quo at GI Conference
Impactful Studies Challenge the Status Quo at GI Conference

August 16th 2024

Evorpacept Shows Promising Efficacy in HER2-Positive Gastric and GEJ Cancers
Evorpacept Shows Promising Efficacy in HER2-Positive Gastric and GEJ Cancers

August 1st 2024